It was a very hot day in late summer. I was a young dad working in a local wood mill. It was dangerous, back-breaking work that paid very little. In the year I worked there, only four other people hadn’t quit and been replaced with new faces. Those of us who stayed did so just because there was no other work to find to support our families.

On this day all of us were covered in sweat and dust. When I looked around, every face I saw looked angry and frustrated. Suddenly, a voice called out, “Hey! There’s a deer in here,” A lost little female deer had wandered through the open loading bay doors and was now cowering in between the huge stacks of wood. All of us stopped working immediately and went looking for her as she ran about looking for a way out.

Now most people where I live hunt deer for meat in the fall but also treat them with great kindness the rest of the year. Many will even buy 50 bags of corn to help feed them during the harsh winter months. It was no surprise then that all of us were soon quickly working together to free this little creature. By blocking off all the other routes, we were able to guide her search back to the open bay doors. We watched as she jumped out of the building and back into the woods. Then we walked back in to work. I noticed something, though. On every face there was a joyful smile. It was as if this one single act of kindness had energized us again and reminded us of what life is all about.

An era in which an Alzheimer’s (阿尔兹海默) diagnosis can begin in a doctor’s office is now arriving. Advances in technologies to detect early signs of disease from a blood sample are helping doctors to identify the memory-robbing disorder more accurately and to screen participants more quickly for trials of potential treatments for the more than five million people in the U.S. afflicted with Alzheimer’s. Estimates predict that, by 2030, there will be 76 million people worldwide who will receive a diagnosis of Alzheimer’s or other dementias.

Last fall, a blood test developed by C2N Diagnostics in St Louis, Mo., became available to most of the U.S. as a routine lab test—regulated under the CMS Clinical Laboratory Improvement Amendments (CLIA) program. It has also received a CE mark as a diagnostic medical device in the European Union—indicating it has met safety, health and environmental protection standards for the region.

“The development of a blood-based test for Alzheimer’s disease is just phenomenal,” says Michelle Mielke, a neuroscientist and epidemiologist at the Mayo Clinic. “The field has been thinking about this for a very long time. It’s really been in the last couple of years that the possibility has come to fruition.”

The C2N test, called PrecivityAD, uses an analytic technique known as mass spectrometry (质谱分析技术) to detect specific types of beta-amyloid (β-淀粉样蛋白), a protein fragment that is a pathological (病态的) hallmark of disease. Beta-amyloid proteins accumulate and form plaques (斑块) visible on brain scans two decades before a patient notices memory problems. As plaques build up in the brain, levels of beta-amyloid decline in the surrounding fluid.

Such changes can be measured in spinal (脊髓的) fluid samples—and now in blood, where beta-amyloid concentrations are significantly lower. PrecivityAD is the first blood test for Alzheimer’s to be cleared for widespread use and one of a new generation of such assays that could enable early detection of the leading neurodegenerative disease—perhaps decades before the onset of the first symptoms.

You are what you eat-and what you eat may be encoded in your DNA. Studies have indicated that your genes play a role in determining the foods you find delicious or disgusting. But exactly how big a role they play has been difficult to figure out. “Everything has a genetic component even if it’s small,” says Joanne Cole, a geneticist at the University of Colorado School of Medicine. “We know that there is some genetic contribution to why we eat the foods we eat. Can we take the next step and actually locate the regions in the genome (基因)?”

New research led by Cole has gotten a step closer. Through a large-scale genomics analysis, her team has identified 481 genome regions that were directly linked to dietary patterns and food preferences. The findings, which have not yet been peer-reviewed, were presented last month at the American Society for Nutrition’s annual conference.

The team based the new study on a 2020 Nature Communications study by Cole and her colleagues that used data from the U.K. Biobank, a public database of the genetic and health information of 500,000 participants. By scanning genomes, the new analysis was able to identify 194 regions associated with dietary patterns and 287 linked to specific foods such as fruit, cheese, fish, tea and alcohol. Further understanding how genetics impact how we eat could reveal differences in nutritional needs or disease risks.

“One of the problems with a lot of these genomics studies is that they’re very small. They don’t have enough people to really be able to identify genes in ways that are credible. This study had a huge group of people, so it’s really powerful.” says Monica Dus, a geneticist at the University of Michigan. “The other thing that I thought was really great is that there are so many different features that they’re measuring related to diet including cholesterol (胆固醇), the body and socioeconomic backgrounds.” As the research advances, Dus says, such genome analysis could potentially assist health care providers and even policymakers to address larger issues that affect food access and health.

It’s definitely true that it may contribute to making sure there aren’t food deserts-areas which have limited access to fresh, healthy and affordable food or to making sure that there’s a higher minimum wage so that everyone can afford to eat, although the journey ahead remains lengthy and challenging.